Protease addiction and synthetic lethality in cancer

Frontiers in Oncology

Volumn 1, Issue SEP, 2011, Pages

  Freije, José M P ^a   Fraile, Julia M ^a   López Otín, Carlos ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

Autophagy; Degradome; Deubiquitinating enzymes; Proteasome

Indexed keywords

EID: 84861394927     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2011.00025     Document Type: Note

References (62)

1. Adams, J. (2004). The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417-421.
2. Aghajan, M., Jonai, N., Flick, K., Fu, F., Luo, M., Cai, X., Ouni, I., Pierce, N., Tang, X., Lomenick, B., Damoiseaux, R., Hao, R., Del Moral, P. M., Verma, R., Li, Y., Li, C., Houk, K. N., Jung, M. E., Zheng, N., Huang, L., Deshaies, R. J., Kaiser, P., and Huang, J. (2010). Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat. Biotechnol. 28, 738-742.
3. Ashworth, A., Lord, C. J., and Reis-Filho, J. S. (2011). Genetic interactions in cancer progression and treatment. Cell 145, 30-38.
4. Baldwin, A., Grueneberg, D. A., Hellner, K., Sawyer, J., Grace, M., Li, W., Harlow, E., and Munger, K. (2010). Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc. Natl. Acad. Sci. U.S.A. 107, 12463-12468.
5. Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., and Brownell, J. E. (2011). Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat. Rev. Drug Discov. 10, 29-46.
6. Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., Hannon, G., and Sawyers, C. L. (2011). FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471, 523-526.
7. Bommi-Reddy, A., Almeciga, I., Sawyer, J., Geisen, C., Li, W., Harlow, E., Kaelin, W. G. Jr., and Grueneberg, D. A. (2008). Kinase requirements in human cells: III. Altered kinase requirements in VHL-/-cancer cells detected in a pilot synthetic lethal screen. Proc. Natl. Acad. Sci. U.S.A. 105, 16484-16489.
8. Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., and Helleday, T. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917.
9. Chan, D. A., and Giaccia, A. J. (2011). Harnessing synthetic lethal interactions in anticancer drug discovery. Nat. Rev. Drug Discov. 10, 351-364.
10. Chen, D. Y., Liu, H., Takeda, S., Tu, H. C., Sasagawa, S., Van Tine, B. A., Lu, D., Cheng, E. H., and Hsieh, J. J. (2010). Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis. Cancer Res. 70, 5358-5367.
11. Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., Horner, J. W. II, Cordon-Cardo, C., Yancopoulos, G. D., and DePinho, R. A. (1999). Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468-472.
12. Dai, C., Whitesell, L., Rogers, A. B., and Lindquist, S. (2007). Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130, 1005-1018.
13. Diamandis, E. P., Hudson, T., Kallioniemi, O., Liu, E. T., and Lopez-Otin, C. (2010). Cancer genomes. Clin. Chem. 56, 1660-1664.
14. Eisenhauer, E. A. (2001). From the molecule to the clinic-inhibiting HER2 to treat breast cancer. N. Engl. J. Med. 344, 841-842.
15. Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M., Jackson, S. P., Smith, G. C., and Ashworth, A. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921.
16. Felsher, D. W., and Bishop, J. M. (1999). Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199-207.
17. Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., and Varmus, H. E. (2001). Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249-3262.
18. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., and Chapman, P. B. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
19. Galluzzi, L., Giordanetto, F., and Kroemer, G. (2009). Targeting HSP70 for cancer therapy. Mol. Cell 36, 176-177.
20. Galluzzi, L., Vitale, I., and Kroemer, G. (2011). Past, present, and future of molecular and cellular oncology. Front. Oncol. 1:1. doi: 10.3389/fonc.2011.00001
21. Guo, J. Y., Chen, H. Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M., Karantza, V., Coller, H. A., Dipaola, R. S., Gelinas, C., Rabinowitz, J. D., and White, E. (2011). Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 25, 460-470.
22. Haber, D. A., Gray, N. S., and Baselga, J. (2011). The evolving war on cancer. Cell 145, 19-24.
23. Haber, D. A., and Settleman, J. (2007). Cancer: drivers and passengers. Nature 446, 145-146.
24. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
25. Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C. J., Van den Abbeele, A. D., Druker, B. J., Kiese, B., Eisenberg, B., Roberts, P. J., Singer, S., Fletcher, C. D., Silberman, S., Dimitrijevic, S., and Fletcher, J. A. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349.
26. Hsieh, J. J., Cheng, E. H., and Korsmeyer, S. J. (2003). Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell 115, 293-303.
27. Huettner, C. S., Zhang, P., Van Etten, R. A., and Tenen, D. G. (2000). Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 24, 57-60.
28. Jordan, M. A., and Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253-265.
29. Kaelin, W. G. Jr. (2005). The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689-698.
30. Knauer, S. K., Fetz, V., Rabenstein, J., Friedl, S., Hofmann, B., Sabiani, S., Schröder, E., Kunst, L., Proschak, E., Thines, E., Kindler, T., Schneider, G., Marschalek, R., Stauber, R. H., and Bier, C. (2011). Bioassays to monitor taspase1 function for the identification of pharmacogenetic inhibitors. PLoS ONE 6, e18253. doi: 10.1371/journal.pone.0018253
31. Kondratyev, M., Kreso, A., Hallett, R. M., Girgis-Gabardo, A., Barcelon, M. E., Ilieva, D., Ware, C., Majumder, P. K., and Hassell, J. A. (2011). Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene. doi: 10.1038/onc.2011.212. [Epub ahead of print].
32. Kwak, E. L., Bang, Y. J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. H., Dezube, B. J., Jänne, P. A., Costa, D. B., Varella-Garcia, M., Kim, W. H., Lynch, T. J., Fidias, P., Stubbs, H., Engelman, J. A., Sequist, L. V., Tan, W., Gandhi, L., Mino-Kenudson, M., Wei, G. C., Shreeve, S. M., Ratain, M. J., Settleman, J., Christensen, J. G., Haber, D. A., Wilner, K., Salgia, R., Shapiro, G. I., Clark, J. W., and Iafrate, A. J. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703.
33. Leu, J. I., Pimkina, J., Frank, A., Murphy, M. E., and George, D. L. (2009). A small molecule inhibitor of inducible heat shock protein 70. Mol. Cell 36, 15-27.
34. Liu, H., Buus, R., Clague, M. J., and Urbe, S. (2009). Regulation of ErbB2 receptor status by the proteasomal DUB POH1. PLoS ONE 4, e5544. doi: 10.1371/journal.pone.0005544
35. Lopez-Otin, C., and Bond, J. S. (2008). Proteases: multifunctional enzymes in life and disease. J. Biol. Chem. 283, 30433-30437.
36. Lopez-Otin, C., and Hunter, T. (2010). The regulatory crosstalk between kinases and proteases in cancer. Nat. Rev. Cancer 10, 278-292.
37. Lopez-Otin, C., and Matrisian, L. M. (2007). Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800-808.
38. Lovejoy, C. A., Xu, X., Bansbach, C. E., Glick, G. G., Zhao, R., Ye, F., Sirbu, B. M., Titus, L. C., Shyr, Y., and Cortez, D. (2009). Functional genomic screens identify CINP as a genome maintenance protein. Proc. Natl. Acad. Sci. U.S.A. 106, 19304-19309.
39. Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K. K., and Elledge, S. J. (2009a). A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848.
40. Luo, J., Solimini, N. L., and Elledge, S. J. (2009b). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837.
41. Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., Nukiwa, T., and North-East Japan Study Group. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388.
42. Navon, A., and Ciechanover, A. (2009). The 26 S proteasome: from basic mechanisms to drug targeting. J. Biol. Chem. 284, 33713-33718.
43. Orlicky, S., Tang, X., Neduva, V., Elowe, N., Brown, E. D., Sicheri, F., and Tyers, M. (2010). An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat. Biotechnol. 28, 733-737.
44. Overall, C. M., and Lopez-Otin, C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2, 657-672.
45. Peggs, K., and Mackinnon, S. (2003). Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N. Engl. J. Med. 348, 1048-1050.
46. Pelengaris, S., Khan, M., and Evan, G. I. (2002). Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109, 321-334.
47. Pelengaris, S., Littlewood, T., Khan, M., Elia, G., and Evan, G. (1999). Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3, 565-577.
48. Real, P. J., Tosello, V., Palomero, T., Castillo, M., Hernando, E., De Stanchina, E., Sulis, M. L., Barnes, K., Sawai, C., Homminga, I., Meijerink, J., Aifantis, I., Basso, G., Cordon-Cardo, C., Ai, W., and Ferrando, A. (2009). Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat. Med. 15, 50-58.
49. Rehman, F. L., Lord, C. J., and Ashworth, A. (2010). Synthetic lethal approaches to breast cancer therapy. Nat. Rev. Clin. Oncol. 7, 718-724.
50. Shaffer, A. L., Emre, N. C., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., Zeng, Y., Chen, B., Epstein, J., and Staudt, L. M. (2008). IRF4 addiction in multiple myeloma. Nature 454, 226-231.
51. Shan, J., Zhao, W., and Gu, W. (2009). Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol. Cell 36, 469-476.
52. Sharma, S. V., and Settleman, J. (2007). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214-3231.
53. Solimini, N. L., Luo, J., and Elledge, S. J. (2007). Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130, 986-988.
54. Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., Cullis, C. A., Doucette, A., Garnsey, J. J., Gaulin, J. L., Gershman, R. E., Lublinsky, A. R., McDonald, A., Mizutani, H., Narayanan, U., Olhava, E. J., Peluso, S., Rezaei, M., Sintchak, M. D., Talreja, T., Thomas, M. P., Traore, T., Vyskocil, S., Weatherhead, G. S., Yu, J., Zhang, J., Dick, L. R., Claiborne, C. F., Rolfe, M., Bolen, J. B., and Langston, S. P. (2009). An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736.
55. Takeda, S., Chen, D. Y., Westergard, T. D., Fisher, J. K., Rubens, J. A., Sasagawa, S., Kan, J. T., Korsmeyer, S. J., Cheng, E. H., and Hsieh, J. J. (2006). Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev. 20, 2397-2409.
56. Turk, B. (2006). Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5, 785-799.
57. Weinstein, I. B. (2002). Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297, 63-64.
58. Weinstein, I. B., and Joe, A. (2008). Oncogene addiction. Cancer Res. 68, 3077-3080; discussion 3080.
59. Weinstein, I. B., and Joe, A. K. (2006). Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3, 448-457.
60. Wiltshire, T. D., Lovejoy, C. A., Wang, T., Xia, F., O'Connor, M. J., and Cortez, D. (2010). Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. J. Biol. Chem. 285, 14565-14571.
61. Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., Silliman, N., Szabo, S., Dezso, Z., Ustyanksky, V., Nikolskaya, T., Nikolsky, Y., Karchin, R., Wilson, P. A., Kaminker, J. S., Zhang, Z., Croshaw, R., Willis, J., Dawson, D., Shipitsin, M., Willson, J. K., Sukumar, S., Polyak, K., Park, B. H., Pethiyagoda, C. L., Pant, P. V., Ballinger, D. G., Sparks, A. B., Hartigan, J., Smith, D. R., Suh, E., Papadopoulos, N., Buckhaults, P., Markowitz, S. D., Parmigiani, G., Kinzler, K. W., Velculescu, V. E., and Vogelstein, B. (2007). The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113.
62. Zhou, H., Spicuglia, S., Hsieh, J. J., Mitsiou, D. J., Hoiby, T., Veenstra, G. J., Korsmeyer, S. J., and Stunnenberg, H. G. (2006). Uncleaved TFIIA is a substrate for taspase 1 and active in transcription. Mol. Cell. Biol. 26, 2728-2735.